Research Commentary
Evidence-Based Dermatology
December 2013

Practicing Prevention With Probiotics

Author Affiliations
  • 1Department of Dermatology, Harvard Medical School, Boston, Massachusetts
  • 2Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
  • 3Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Dermatol. 2013;149(12):1422-1424. doi:10.1001/jamadermatol.2013.6226

Clostridium difficile–associated disease (CDAD) represents a substantial and increasing cause of morbidity, mortality, and health care spending.1 A primary risk factor for CDAD is systemic antibiotic use; disruption of normal gastrointestinal flora is thought to limit resistance to colonization by pathogenic bacteria including C difficile, resulting in potentially serious antibiotic-associated diarrhea. Whereas individuals often contract CDAD as a hospital-acquired infection, increasing numbers of community-acquired CDAD cases are being recognized.2 Limited data on community-acquired CDAD point to several antibiotics—particularly clindamycin, but also β-lactam antibiotics, fluoroquinolones, and macrolides—whose use may pose a risk.3

First Page Preview View Large
First page PDF preview
First page PDF preview